Paris, France, Cambridge, USA, May 13, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the first quarter of 2016.
Nanobiotix’s revenue during the first quarter of 2016 corresponds to the upfront payment (pro-rata share) from Taiwan-based PharmaEngine. This is within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead NanoXray product, NBTXR3 in the Asia-Pacific region. The upfront payment amounted €810,640 and, as before, is distributed using the straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. In total, revenue for the Q1 amounted to €45,847 over the period which is fully in line with Company’s expectations.
On January 4, 2016, the Company announced that the US Food and Drug Administration (FDA) had approved the Company’s Investigational New Drug (IND) application. This allows Nanobiotix to launch its first clinical study in the US for its lead product NBTXR3 in prostate cancer, a new and very significant indication. With the addition of this prostate cancer trial, NBTXR3 is now tested in a total of six indications.
On January 5, 2016, Nanobiotix started a new research program in immuno-oncology with its lead product NBTXR3. The first preclinical results are expected later this year. These preclinical results should establish the proof of concept for potential combination of NBTXR3 with immuno-oncology approaches across oncology and could open new perspectives for potential deals.
Moreover, On March 11, 2016, the Company successfully completed a €21.3 million private placement of new ordinary shares. The new ordinary shares were issued primarily with life sciences specialist investors, the majority of which are from the United States.
Next financial press release: revenue for Q2 2016, on July 13, 2016
Nanobiotix informs that its Annual General Meeting will be held on June 23, 2016 at 2pm, Novotel Paris Vaugirard Montparnasse Hotel – 257-263, rue de Vaugirard 75015 Paris
Notes To Editors
About NANOBIOTIX: www.nanobiotix.com/fr
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck Cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Issued for and on behalf of Nanobiotix by Instinctif Partners.
For more information please contact:
Head of Communication and Public Affairs
+33 (0) 1 40 26 07 55
France - NewCap
+33 (0) 6 88 20 35 59
Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered by the French Financial Markets Authority (Autorité des marchés financiers) on January 12, 2016 under number R.16-001 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
Melanie Toyne-SewellManaging Partner